DE69924536D1 - Spülende lösung und methoden zur hemmung von schmerzen und entzündungen - Google Patents
Spülende lösung und methoden zur hemmung von schmerzen und entzündungenInfo
- Publication number
- DE69924536D1 DE69924536D1 DE69924536T DE69924536T DE69924536D1 DE 69924536 D1 DE69924536 D1 DE 69924536D1 DE 69924536 T DE69924536 T DE 69924536T DE 69924536 T DE69924536 T DE 69924536T DE 69924536 D1 DE69924536 D1 DE 69924536D1
- Authority
- DE
- Germany
- Prior art keywords
- antagonist
- pain
- tetrahydro
- solution
- inflammation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title abstract 4
- 206010061218 Inflammation Diseases 0.000 title abstract 3
- 230000004054 inflammatory process Effects 0.000 title abstract 3
- 230000002401 inhibitory effect Effects 0.000 title abstract 3
- 239000005557 antagonist Substances 0.000 abstract 3
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 abstract 2
- 206010052428 Wound Diseases 0.000 abstract 2
- 208000027418 Wounds and injury Diseases 0.000 abstract 2
- 238000001356 surgical procedure Methods 0.000 abstract 2
- ZNXAJGZPUQOEDZ-UHFFFAOYSA-N 6-ethyl-4,5,7,8-tetrahydro-[1,3]oxazolo[4,5-d]azepin-2-amine Chemical compound C1CN(CC)CCC2=C1OC(N)=N2 ZNXAJGZPUQOEDZ-UHFFFAOYSA-N 0.000 abstract 1
- DHSSDEDRBUKTQY-UHFFFAOYSA-N 6-prop-2-enyl-4,5,7,8-tetrahydrothiazolo[4,5-d]azepin-2-amine Chemical compound C1CN(CC=C)CCC2=C1N=C(N)S2 DHSSDEDRBUKTQY-UHFFFAOYSA-N 0.000 abstract 1
- 229940127291 Calcium channel antagonist Drugs 0.000 abstract 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 abstract 1
- 229940122204 Cyclooxygenase inhibitor Drugs 0.000 abstract 1
- 102000016924 KATP Channels Human genes 0.000 abstract 1
- 108010053914 KATP Channels Proteins 0.000 abstract 1
- 102000000033 Purinergic Receptors Human genes 0.000 abstract 1
- 108010080192 Purinergic Receptors Proteins 0.000 abstract 1
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 abstract 1
- 239000000739 antihistaminic agent Substances 0.000 abstract 1
- 239000000480 calcium channel blocker Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229960002896 clonidine Drugs 0.000 abstract 1
- HRLIOXLXPOHXTA-NSHDSACASA-N dexmedetomidine Chemical compound C1([C@@H](C)C=2C(=C(C)C=CC=2)C)=CN=C[N]1 HRLIOXLXPOHXTA-NSHDSACASA-N 0.000 abstract 1
- 229960004253 dexmedetomidine Drugs 0.000 abstract 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 abstract 1
- 125000001841 imino group Chemical group [H]N=* 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000002262 irrigation Effects 0.000 abstract 1
- 238000003973 irrigation Methods 0.000 abstract 1
- 239000002742 neurokinin 1 receptor antagonist Substances 0.000 abstract 1
- 239000002746 neurokinin 2 receptor antagonist Substances 0.000 abstract 1
- 239000003402 opiate agonist Substances 0.000 abstract 1
- 239000004036 potassium channel stimulating agent Substances 0.000 abstract 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
- 239000003215 serotonin 5-HT2 receptor antagonist Substances 0.000 abstract 1
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 abstract 1
- 239000000952 serotonin receptor agonist Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10502998P | 1998-10-20 | 1998-10-20 | |
| US105029P | 1998-10-20 | ||
| PCT/US1999/024672 WO2000023066A2 (en) | 1998-10-20 | 1999-10-20 | Irrigation solution and method for inhibition of pain and inflammation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69924536D1 true DE69924536D1 (de) | 2005-05-04 |
| DE69924536T2 DE69924536T2 (de) | 2006-02-16 |
Family
ID=22303668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69924536T Expired - Lifetime DE69924536T2 (de) | 1998-10-20 | 1999-10-20 | Spülende lösung und methoden zur hemmung von schmerzen und entzündungen |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1227807B1 (de) |
| AT (1) | ATE291907T1 (de) |
| AU (1) | AU1319200A (de) |
| DE (1) | DE69924536T2 (de) |
| ES (1) | ES2239466T3 (de) |
| HK (1) | HK1048259B (de) |
| WO (1) | WO2000023066A2 (de) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6294553B1 (en) * | 2000-02-15 | 2001-09-25 | Allergan Sales, Inc. | Method for treating ocular pain |
| US7345065B2 (en) * | 2002-05-21 | 2008-03-18 | Allergan, Inc. | Methods and compositions for alleviating pain |
| CN1684701B (zh) | 2002-07-30 | 2012-10-17 | 奥默罗斯公司 | 眼科冲洗液及方法 |
| BRPI0807972A2 (pt) | 2007-01-24 | 2014-06-10 | Glaxo Group Ltd | Composições farmacêuticas compreendendo 3,5-diamino-6-(2,3-diclofenil)-l,2,4-triazina ou r(-)-2,4-diamino-5-(2,3-diclorofenil)-6-fluorometilpirim idina e uma nk1 |
| HUE033143T2 (en) | 2010-03-26 | 2017-11-28 | Galderma Res & Dev | Preparations containing brimonidine for the treatment of erythema |
| EP2768502A2 (de) | 2011-10-19 | 2014-08-27 | Galderma S.A. | Verfahren zur verringerung gesichtsrötung mittels systematischer verwendung von phosphodiesterase-typ 5-hemmern |
| AU2012352528B9 (en) | 2011-12-11 | 2017-11-02 | Baudax Bio, Inc. | Intranasal dexmedetomidine compositions and methods of use thereof |
| AU2013201465B2 (en) | 2012-10-24 | 2016-03-03 | Rayner Surgical (Ireland) Limited | Stable preservative-free mydriatic and anti-inflammatory solutions for injection |
| EP3054930B1 (de) | 2013-10-07 | 2020-12-02 | Teikoku Pharma USA, Inc. | Verfahren und zusammensetzungen zur transdermalen verabreichung einer nicht-sedierenden menge an descmedetomidin |
| US10772871B2 (en) | 2013-10-07 | 2020-09-15 | Teikoku Pharma Usa, Inc. | Dexmedetomidine transdermal delivery devices and methods for using the same |
| TWI709417B (zh) | 2013-10-07 | 2020-11-11 | 美商帝國製藥美國股份有限公司 | 使用右美托咪啶經皮組成物用於治療注意力不足過動症、焦慮及失眠的方法及組成物 |
| TWI705812B (zh) | 2014-12-01 | 2020-10-01 | 奥默羅斯公司 | 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2040510C3 (de) * | 1970-08-14 | 1980-03-06 | Dr. Karl Thomae Gmbh, 7950 Biberach | Oxazole- und Thiazole eckige Klammer auf 5,4-d] azepin- Derivate |
| US4659714A (en) * | 1984-03-27 | 1987-04-21 | Dentsply, Ltd. | Anesthetic methods for mammals |
| DE3583900D1 (de) * | 1984-06-06 | 1991-10-02 | Abbott Lab | Adrenergische verbindungen. |
| US5212196A (en) * | 1986-10-21 | 1993-05-18 | Alcon Laboratories, Inc. | Control of post-surgical intraocular pressure using clonidine derivatives |
| FI894911A0 (fi) * | 1989-10-17 | 1989-10-17 | Farmos Oy | En terapeutiskt vaerdefull foerening. |
| DK0538469T3 (da) * | 1990-02-07 | 1996-01-15 | Nippon Shinyaku Co Ltd | Sulfonanilidderivat og lægemiddel |
| JPH06507392A (ja) * | 1991-02-26 | 1994-08-25 | エイアールシー １，インコーポレイテッド | 交感神経性の持続性疼痛の治療のための組成物および方法 |
| US6323204B1 (en) * | 1993-10-13 | 2001-11-27 | Allergan | Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives |
| JP3683908B2 (ja) * | 1993-10-13 | 2005-08-17 | アラーガン、インコーポレイテッド | （２−イミダゾリン−２−イルアミノ）キノキサリン誘導体の使用方法 |
| BR9408342A (pt) * | 1993-12-17 | 1997-08-19 | Procter & Gamble | Compostos de 6-(2-imidazolinilamino) quinoxalina úteis como agonistas de adrenoceptores de alfa-2 |
| RU2180852C2 (ru) * | 1994-12-12 | 2002-03-27 | Омерос Медикл Системс, Инк. | Ингибирующий раствор и способ подавления боли, воспаления или спазма |
| KR100517210B1 (ko) * | 1994-12-12 | 2006-06-07 | 오메로스 코포레이션 | 통증,염증및경련억제용관주용액 |
| GB9704370D0 (en) * | 1997-03-03 | 1997-04-23 | Chiroscience Ltd | Levobupivacaine and its use |
| DE19758564A1 (de) * | 1997-11-11 | 1999-08-26 | Gruenenthal Gmbh | Formulierung einer Kombination aus Morphin und einem alpha¶2¶-adrenergem Agonisten und deren Verwendung |
-
1999
- 1999-10-20 WO PCT/US1999/024672 patent/WO2000023066A2/en active Application Filing
- 1999-10-20 DE DE69924536T patent/DE69924536T2/de not_active Expired - Lifetime
- 1999-10-20 ES ES99956629T patent/ES2239466T3/es not_active Expired - Lifetime
- 1999-10-20 AU AU13192/00A patent/AU1319200A/en not_active Abandoned
- 1999-10-20 EP EP99956629A patent/EP1227807B1/de not_active Expired - Lifetime
- 1999-10-20 AT AT99956629T patent/ATE291907T1/de not_active IP Right Cessation
-
2003
- 2003-01-20 HK HK03100488.6A patent/HK1048259B/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1227807A2 (de) | 2002-08-07 |
| WO2000023066A3 (en) | 2001-08-23 |
| HK1048259A1 (en) | 2003-03-28 |
| AU1319200A (en) | 2000-05-08 |
| HK1048259B (zh) | 2005-06-03 |
| ATE291907T1 (de) | 2005-04-15 |
| ES2239466T3 (es) | 2005-09-16 |
| WO2000023066A2 (en) | 2000-04-27 |
| EP1227807B1 (de) | 2005-03-30 |
| DE69924536T2 (de) | 2006-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69924536D1 (de) | Spülende lösung und methoden zur hemmung von schmerzen und entzündungen | |
| CA2206119A1 (en) | Irrigation solution and method for inhibition of pain, inflammation and spasm | |
| EA200400966A1 (ru) | Новые лекарственные формы замещенного бензимидазола и способ их применения | |
| NO971546D0 (no) | Reumatoid artritt-middel inneholdende IL-6-antagonist som aktiv bestanddel | |
| ATE204164T1 (de) | Pflaster zur behandlung von nagelmykosen | |
| BR0112292A (pt) | Composto, composição farmacêutica, método para tratar ou prevenir disfunções tromboembólicas e uso de um composto | |
| DE60043587D1 (de) | Mittel für erkrankungen assoziert mit knochensubstanzverlust | |
| ECSP055809A (es) | Inhibidores 4-oxo-1-(3-fenil sustituido)-1,4-dihidro-1,8-naftiridina-3-carboxamida de la fosfodiesterasa-4 | |
| WO2005037259A3 (en) | Methods and compositions for the prevention or treatment of neoplasia comprising a cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist | |
| WO2004105757A3 (en) | Use of rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy | |
| WO2002040021A3 (en) | Methods for inhibiting the transmission of hiv using topically applied substituted 6-benzyl-4-oxopyrimidines | |
| NO982006L (no) | Terapeutisk preparat for transdermal tilf°rsel av virksomme stoffer gjennom huden | |
| WO2005044194A3 (en) | TREATMENT OR PREVENTION OF NEOPLASIA BY USE OF AN Hsp90 INHIBITOR | |
| HUP0202687A2 (hu) | Gyorsan ható szelektív szerotonin-újrafelvételt gátlókat alkalmazó eljárások nemi működési zavarok kezelésére | |
| DE69734405D1 (de) | Verwendung von CS-866 (Olmersartan) zur Herstellung eines Medikaments für die Behandlung von Arteriosklerose | |
| WO2000023062A3 (en) | Irrigation solution and method for inhibition of pain and inflammation | |
| ATE266420T1 (de) | Kombinationspräparat, das selektive nmda nr2b- antagonisten und cox-2 inhibitoren enthält | |
| ATE371454T1 (de) | Antagonisten der prostaglandin ep2 und/oder ep4 rezeptoren zur behandlung von menorrhagie | |
| BR0317461A (pt) | Composições tópicas absorventes de óleo e método para o uso das mesmas | |
| BR9910678A (pt) | Composto, composição farmacêutica, método para traramento ou prevenção de uma doença inflamatória, método para tratamento de uma condição ou uma doença mediada por mmps, tnf, agrecanase, ou um composto dos mesmos, em um mamìfero, método de redução de nìveis de tnf em pacientes, sem a inibição de mmps, método para tratamento de uma condição ou uma doença e uso de um novo composto | |
| IS7517A (is) | Efnasambönd sem nýtast í meðferð við miltisbrandiog hindra banvænan þátt | |
| ES2088128T3 (es) | Aminosulfonilureas inhibidoras de acat. | |
| DE69937070D1 (de) | Spüllösung und verfahren zur schmerzlinderung und entzündungshemmung | |
| WO2000048581A3 (en) | Use of 5-ht3 receptor antagonists for treating musculoeskeletal diseases | |
| KR970701044A (ko) | 콜린에스테라제 활성제 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |